Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1709-1717

  Seguin, Johanne ^a   Nicolazzi, Céline ^a   Mignet, Nathalie ^a   Scherman, Daniel ^a   Chabot, Guy G ^a  

^a Centre National de la Recherche Scientifique   (France)

Author keywords

Colon; E selectin; Integrin alpha v beta 3; Lung; Mammary; Melanoma; Mouse tumours; Pancreas; Sarcoma; Vascularization

Indexed keywords

CD31 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; BREAST CANCER; COLON CANCER; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 84868101505     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0428-x     Document Type: Article

References (59)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-8.
2. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641.
3. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 1997;100:S37-9.
4. Otvos L, Kieber-Emmons T, Blaszczyk-Thurin M. Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides. 2002;23:999-1010.
5. Hosotani R, Kawaguchi M, Masui T, Koshiba T, Ida J, Fujimoto K, Wada M, Doi R, Imamura M. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas. 2002;25:e30-5.
6. Langley RR, Russell J, Eppihimer MJ, Alexander SJ, Gerritsen M, Specian RD, Granger DN. Quantification of murine endothelial cell adhesion molecules in solid tumors. Am J Physiol. 1999;277:H1156-66.
7. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alpha v beta 3. Important Adv Oncol. 1996;1996:69-87.
8. Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol. 1996;148:1181-91.
9. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93:9764-9.
10. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83-90.
11. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 1997;71:320-4.
12. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-64.
13. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-30.
14. Weis SM, Cheresh DA. Alpha v Integrins in Angiogenesis and Cancer. Cold Spring Harb Perspect Med. 2011;1:a006478.
15. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev. 2001;53:135-54.
16. Nguyen M, Eilber FR, Defrees S. Novel synthetic analogs of sialyl Lewis X can inhibit angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 1996;228:716-23.
17. Yasuda M, Shimizu S, Ohhinata K, Naito S, Tokuyama S, Mori Y, Kiuchi Y, Yamamoto T. Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis. Am J Physiol Cell Physiol. 2002;282:C917-25.
18. Mannori G, Santoro D, Carter L, Corless C, Nelson RM, Bevilacqua MP. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol. 1997;151:233-43.
19. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol. 2001;14:1126-32.
20. Polin L, Corbett TH, Roberts BJ, Lawson AJ, Leopold III WR, White K, Kushner J, Hazeldine S, Moore R, Rake J, Horwitz JP. Transplantable syngeneic rodent tumors: Solid tumors of mice. In: Teicher BA, editor. Tumors models in cancer research, Cancer Drug Discovery and Development. New York: Springer Science & Business Media LLC; 2011. p. 43-78.
21. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218-24.
22. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434-9.
23. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 1977;40:2660-80.
24. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep. 1978;62:1471-88.
25. Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983;67:905-22.
26. Liang J, Moore RE, Moher ED, Munroe JE, Al-awar RS, Hay DA, Varie DL, Zhang TY, Aikins JA, Martinelli MJ, Shih C, Ray JE, Gibson LL, Vasudevan V, Polin L, White K, Kushner J, Simpson C, Pugh S, Corbett TH. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors. Invest New Drugs. 2005;23:213-24.
27. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-26.
28. Glasgow LA, Crane Jr JL, Kern ER, Youngner JS. Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo. Cancer Treat Rep. 1978;62:1881-8.
29. Bertram JS, Janik P. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett. 1980;11:63-73.
30. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407-24.
31. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer. 1999;80:1697-707.
32. Strohmeyer D. Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res. 1999;19:1557-61.
33. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86:1566-77.
34. Boles KS, Schmieder AH, Koch AW, Carano RA, Wu Y, Caruthers SD, Tong RK, Stawicki S, Hu G, Scott MJ, Zhang H, Reynolds BA, Wickline SA, Lanza GM. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 2010;24:4262-70.
35. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis. 2002;19:427-36.
36. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, Cheresh DA. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15:1163-9.
37. Nelson H, Ramsey PS, Donohue JH, Wold LE. Cell adhesion molecule expression within the microvasculature of human colorectal malignancies. Clin Immunol Immunopathol. 1994;72:129-36.
38. Fox SB, Turner GD, Gatter KC, Harris AL. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol. 1995;177:369-76.
39. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets. 2007;11:1473-91.
40. Jubeli E, Moine L, Vergnaud-Gauduchon J, Barratt G. E-selectin as a target for drug delivery and molecular imaging. J Control Release. 2012;158:194-206.
41. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol. 2002;160:195-204.
42. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8:27-34.
43. Tucker GC. Inhibitors of integrins. Curr Opin Pharmacol. 2002;2:394-402.
44. Parkes RJ, Hart SL. Adhesion molecules and gene transfer. Adv Drug Deliv Rev. 2000;44:135-52.
45. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001;8:969-76.
46. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-7.
47. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, Cybulsky MI, Tosi PF, Nicolau C, Gimbrone Jr MA. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A. 1997;94:8795-800.
48. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-61.
49. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-8.
50. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
51. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10:753-68.
52. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1:102-26.
53. Liu ZJ, Tian R, Li Y, An W, Zhuge Y, Livingstone AS, Velazquez OC. Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin. Ann Surg. 2011;254:450-6.
54. Formelli F, Rossi C, Supino R, Parmiani G. In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br J Cancer. 1986;54:223-33.
55. Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. Invest New Drugs. 1993;11:263-77.
56. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845-52.
57. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res. 1982;42:1707-15.
58. LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold III WR, Corbett TH. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14:349-56.
59. DeWys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res. 1972;32:374-9.